ClinicalTrials.gg
RecruitingNCT05629559Updated Feb 21, 2025

4D-310 in Adults With Fabry Disease and Cardiac Involvement

A Phase 1/2 interventional study of 4D-310 in Fabry Disease, sponsored by 4D Molecular Therapeutics. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by 4D Molecular Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Fabry Disease with a site in Australia — 2 open to participants now, 6 under way, 2 of them phase 3. Fabry Disease · Australia.

Planned enrollment
16th of 22
18 · median 36
Started
2022
with 2 others
Phase 1/2
4 of 27
1 open now
Registered
27th of 27
by date
Lead sponsor
1 of 27
4D Molecular Therapeutics

Among the 27 studies in Fabry Disease with a site in Australia, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 1/2, and was the 27th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 27 studies in Fabry Disease with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Fabry Disease with a site in Australia, or all of them as a file.
02

Study summary

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement

Read the detailed description

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement

03

Conditions studied

  • Fabry Disease

Keywords

  • Lysosomal Storage Diseases
  • Nervous System Brain Diseases
  • Metabolic
  • Inborn Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Cerebral Small Vessel Diseases
  • Cerebrovascular Disorders
  • Vascular Diseases
  • Cardiovascular Diseases
  • Genetic Diseases
  • X-Linked
  • Inborn
  • Metabolic Diseases
  • Lipid Metabolism Disorders
  • Sphingolipidoses
  • Metabolism
  • Inborn Errors
  • Lipidoses
  • Lipid Metabolism
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 to ≤65 years of age
  2. Pathogenic GLA mutation consistent with Fabry Disease
  3. Confirmed diagnosis of classic or late-onset Fabry disease with cardiac involvement
  4. Intolerant of ERT, unable or unwilling to receive ERT, or progressive disease despite ERT or migalastat
  5. Individuals receiving ERT, must be on a stable dose for at least 6 months
  6. Agree to use highly effective

Exclusion criteria

Exclusion Criteria:

  1. Presence of pre-existing antibodies to 4D-310 capsid or to AGA
  2. \<65 mL/min/1.73 m2
  3. Undergone kidney transplantation or currently on hemodialysis or peritoneal dialysis
  4. , active or chronic or C,
  5. Evidence of liver disease, severe pulmonary disease or diabetes with poor glycemic control
  6. History of stroke or within the last 12 months, or other significant thromboembolic disease history (e.g. pulmonary embolism)
  7. to systemic therapy or therapy
  8. Chronic steroid use, defined as ≥ 3 months of oral corticosteroid use within the last 12 months.
  9. Moderately severe to severe cardiovascular disease or uncontrolled hypertension
  10. of \<45% on echocardiogram (ECHO)
  11. Currently receiving drug, device or therapy or having ever received gene therapy
  12. History of infusion related response to ERT or any adverse reaction leading to ERT discontinuation
  13. History of cancer within 2 years (exceptions include non-melanoma skin cancer, localized prostate cancer treated with curative intent)
  14. Pregnant or breast-feeding

Note: Other inclusion and exclusion criteria apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    4D-310 Dose Level -1

    Single IV administration of 4D-310 Dose Level -1

    Biological: 4D-310

  • Experimental
    4D-310 Dose Level 2

    Single IV administration of 4D-310 Dose Level 2

    Biological: 4D-310

  • Experimental
    4D-310 Dose Level 3

    Single IV administration of 4D-310 at Dose Level 3

    Biological: 4D-310

  • Experimental
    4D-310 Dose Level 1 (No longer enrolling)

    No longer enrolling - Single IV administration of 4D-310 at Dose Level 1

    Biological: 4D-310

Interventions

  • Biological4D-310

    Single IV administration of 4D-310

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Incidence and severity of adverse events following a single IV dose of 4D-310intravenous (IV) dose

    Time frame: 1 year

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Jun 2026, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Nov 29, 2022
StartActual
Oct 16, 2022
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2030
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05629559
Lead sponsor
4D Molecular Therapeutics
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Oct 16, 2022
Primary completion
Jun 2026 (estimated)
Completion
Jun 2030 (estimated)
Last update
Feb 21, 2025

Study contacts

4DMT Patient Advocacy
Contact
clinicaltrials@4DMT.com
(888) 748-8881
Alan H Cohen, MD
study director · 4D Molecular Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion